Could an HIV Drug Beat Strep Throat, Flesh-Eating Bacteria?

With antibiotic resistance on the rise, scientists are looking for innovative ways to combat bacterial infections.

| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

StreptolysinThe fight against bacteria that cause strep throat and other illnesses could get help from an HIV drug.American Chemical SocietyThe pathogen that causes conditions from strep throat to flesh-eating disease is among them, but scientists have now found a tool that could help them fight it: a drug approved to treat HIV. Their work, appearing in the American Chemical Society journal ACS Chemical Biology, could someday lead to new treatments.

Douglas A. Mitchell and colleagues point out that Streptococcus pyogenes is responsible for more than 600 million illnesses and 500,000 deaths globally every year. A major factor in the pathogen's ability to cause disease is its production of a toxin called streptolysin S, or SLS. If scientists could figure out a way to jam the bacterial machinery that makes the compound, they could develop new therapies to fight the pathogen and slow the spread of antibiotic resistance. But not much is known about how S. pyogenes makes SLS. Mitchell's team wanted to start filling in the blanks.

The researchers turned to an HIV drug called nelfinavir. Although the drug's target is an HIV protein, it is also known to incidentally block a key enzyme in patients. That enzyme is related to one in S. pyogenes that is critical for producing SLS. The scientists made several nelfinavir-like compounds that stopped the bacteria from making the toxin in lab tests. They conclude that the drug and its variants could help future efforts to understand how the deadly bacteria works and how to stop it.

Want to stay up to date on the latest lab management news?

Subscribe to our free Lab Manager Monitor Newsletter.

Is the form not loading? If you use an ad blocker or browser privacy features, try turning them off and refresh the page.

The authors acknowledge funding from the National Institutes of Health.

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - January/February 2025

Energizing Leadership in Action

The science-backed behaviors that help leaders inspire thriving teams and organizations

Lab Manager January/February 2025 Cover Image